Alfred Chung, MD

Education
06/2020 - Fellowship, Hematology/Oncology, Stanford University
06/2017 - Residency, Internal Medicine, Stanford University
MD, 05/2014 - Medicine, Northwestern University - Feinberg School of Medicine
BSE, 05/2010 - Chemical Engineering, University of Michigan - Ann Arbor
Publications

  1. Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy 2025. PMID: 41104991


  2. Chilakapati N, Patiño-Escobar B, Chen EY, Dalal R, de Montagnac J, Johnson H, Kang AS, Akagi N, Ramos E, Phojanakong P, Salangsang F, Zeng Y, Chari A, Chung A, Kumar AD, Martin TG, Wolf JL, Shy BR, Steri V, Karlon WJ, Kortemme T, Barwick BG, Wiita AP. Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma. bioRxiv : the preprint server for biology 2025. PMID: 40894691


  3. Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin T, Wolf JL, Wong S, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon W, Barwick BG, Wiita A. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. Blood 2025. PMID: 40359480


  4. Zhou P, Mansukhani MM, Yeh R, Lu J, Xia H, Koganti L, Pang J, Toskic D, Scalia S, Ma X, Lee LX, Wong SW, Chung A, Tuchman SA, Fogaren T, Coady Lyons N, Varga C, Lentzsch S, Comenzo RL. Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies. Journal of clinical medicine 2025. PMID: 40565890


  5. Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs 2025. PMID: 40425184


  6. Gaballa MR, Castaneda Puglianini O, Cohen AD, Vogl DT, Chung A, Ferreri CJ, Voorhees PM, Hansen DK, Patel KK. BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement. Blood advances 2024. PMID: 39729503


  7. Badros AZ, Foster L, Anderson LD, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin T, Voorhees PM. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood 2024. PMID: 39331724


  8. Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, Wolf JL, Arora S, Shah N, Chari A, Chung A. Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for Multiple Myeloma. Blood advances 2024. PMID: 38429087


  9. Md OK, Prakash S, Chung A, Wong SW, Kennedy VE. Monoclonal Gammopathy of Anemic Significance? Resolution of Pure Red Cell Aplasia with Daratumumab-based Therapy. The American journal of medicine 2024. PMID: 38401677


  10. Banerjee R, Huang CY, Ryan C, Lee A, Brassil KJ, Moore J, Arora S, Chung A, Wong SW, Wolf J, Martin T, Dhruva A, Shah N. Randomized phase 2 study of digital life coaching during transplantation for myeloma. Bone marrow transplantation 2023. PMID: 37743374


  11. Duvalyan E, Shah N, Lo M, Martin T, Wolf JL, Chung A, Arora S, Huang CY, Wong SW. Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma. Leukemia & lymphoma 2023. PMID: 37599633


  12. Zafar A, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Martin T, Shah N, Banerjee R. Intensity of cyclophosphamide-based bridging therapy before CAR-T therapy in myeloma. Transplantation and cellular therapy 2023. PMID: 37244643


  13. Natsuhara KH, Huang CY, Knoche J, Arora S, Chung A, Martin T, Wolf J, Wong SW, Shah N, Banerjee R. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma. Leukemia & lymphoma 2023. PMID: 37096638


  14. Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Olin RL, Martin T, Shah N, Banerjee R. Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma. Transplantation and cellular therapy 2023. PMID: 36933659


  15. Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, Martin TG, Wolf J, Wong SW, Wiita AP, Shah N. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study. British journal of haematology 2023. PMID: 36846905


  16. Kennedy VE, Natsuhara K, Shah ND, Arora S, Wolf J, Martin TG, Aras MA, Chung A, Wong SW. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis. Current problems in cancer 2023. PMID: 36807996


  17. Rath C, Yoo C, Cheplowitz H, Lo M, Young R, Guglielmo J, Saunders IM, Banerjee R, Young R, Kumar A, Chung A, Rosenberg AS, Costello C, Fine J, Wilson M, Patel N, Banez MT. Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023. PMID: 36731514


  18. Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. British journal of haematology 2022. PMID: 36041779


  19. Chung A, Kaufman GP, Sidana S, Eckhert E, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood advances 2020. PMID: 32027745


  20. Chung A, Liedtke M. Cutaneous plasmablastic plasmacytoma. Blood 2019. PMID: 31805196


  21. Chung A, Liedtke M. Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best practice & research. Clinical haematology 2019. PMID: 30927976


  22. Beel AJ, Demos DS, Chung A, Liao C, Lui NS. Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report. Journal of cardiothoracic surgery 2018. PMID: 29415746


  23. Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer genetics 2017. PMID: 29025582


  24. Rehman A, Hamilton A, Chung A, Baker GA, Wang Z, Zeng X. Differential solute gas response in ionic-liquid-based QCM arrays: elucidating design factors responsible for discriminative explosive gas sensing. Analytical chemistry 2011. PMID: 21863884


  25. Digambaranath JL, Campbell TV, Chung A, McPhail MJ, Stevenson KE, Zohdy MA, Finke JM. An accurate model of polyglutamine. Proteins 2011. PMID: 21337625


  26. Blazer LL, Roman DL, Chung A, Larsen MJ, Greedy BM, Husbands SM, Neubig RR. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Molecular pharmacology 2010. PMID: 20571077